EUCTR2008-006323-31-ES进行中（未招募）1 期
Ensayo fase II, doble ciego, aleatorizado, controlado con placebo, para evaluar la eficacia de AZD6244 (hidrógeno-sulfato), en combinación con Docetaxel, comparado con Docetaxel en monoterapia, en pacientes con cáncer de pulmón no microcítico localmente avanzado o metastásico (estadío IIIB - IV) con mutación KRAS positiva en 2ª línea de tratamientoA Phase II, Double-Blind, Randomised, Placebo-Controlled Study to Assess the Efficacy of AZD6244 (Hyd-Sulfate) in Combination with Docetaxel, Compared with Docetaxel Alone, in 2nd Line Patients with KRAS Mutation Positive Locally Advanced or Metastatic Non Small Cell Lung Cancer (Stage IIIB - IV)
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 87
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Provision of signed, written and dated informed consent prior to any study specific procedures
- •2.Male or female, aged 18 years or older
- •3.Histological or cytological confirmation of locally advanced or metastatic NSCLC (IIIB-IV)
- •4.Failure of 1st line anti-cancer therapy (either radiological documentation of disease progression or due to toxicity) in advanced disease or subsequent relapse of disease following 1st line therapy. See Appendix L for further details. See Section 5.2 for specific 1st line agents not permitted in this study.
- •5.WHO Performance Status 0 ? 1
- •6.Patients must be eligible to receive treatment with docetaxel in accordance with docetaxel product information (available from Sanofi-Aventis, the manufacturer of docetaxel ? see Appendix J for contact details)
- •7.At least one lesion, not previously irradiated, that can be accurately measured as ?10 mm in the longest diameter (LD) with spiral computed tomography (CT) scan or as ?20 mm with conventional techniques (conventional CT, MRI) and which is suitable for accurate repeated measurements
- •8.Tumour sample confirmed as KRAS mutation positive (Note: Sample must be available upon enrolment to ship to AZ appointed central laboratory, or mutation status confirmed locally at AstraZeneca agreed local laboratory using a) allele specific PCR (this includes ARMS?) or b) direct sequencing)
- •9.Evidence of post-menopausal status, or negative urinary or serum pregnancy test for female pre-menopausal patients. Post menopausal females are defined as follows: natural menopause with menses >1 year ago; or radiation-induced oophorectomy with last menses >1 year ago; or chemotherapy-induced menopause with 1 year interval since last menses; or serum FSH and LH and plasma oestradiol levels in the postmenopausal range for the institution; or bilateral oopherectomy or hysterectomy.
- •10.Serum creatinine clearance >50mL/min by either Cockcroft-Gault formula or 24hr urine collection analysis
- •11.Patients should be able to swallow AZD6244/placebo capsules.
- •12. For inclusion in the optional host genetics research study patients must fulfil the following criteria: Provision of optional host genetics research informed consent. If a patient declines to participate in the host genetics research, there will be no penalty or loss of benefit to the patient. A patient who declines host genetics research participation will not be excluded from any other aspect of the main study.
- •13. For inclusion in the optional biomarkers research study patients must fulfil the following criteria: Provision of optional consent for use of residual KRAS tumour and CFDNA serum and plasma samples for additional biomarker research. If a patient declines to participate in the biomarkers research, there will be no penalty or loss of benefit to the patient. A patient who declines biomarkers research participation will not be excluded from any other aspect of the main study.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site)
- •2.Previous randomisation of treatment in the present study
- •3.Mixed small cell and non-small cell lung cancer histology
- •4.Received >1 prior anti-cancer therapy for advanced or metastatic NSCLC (excluding radiotherapy, see exclusions 6 and 9)
- •5.Having received an investigational drug within the 30 days prior to entry, or have not recovered from side effects of an investigational drug
- •6.Receiving or have received systemic anti-cancer therapy within 4 weeks prior to starting study treatment (6 weeks for nitrosoureas, mitomycin, and suramin)
- •7.Prior treatment with a MEK inhibitor or any docetaxel containing regimen (prior treatment with paclitaxel is acceptable)
- •8.Any unresolved toxicity >CTCAE Grade 2 from previous anti-cancer therapy, apart from alopecia
- •9.The last radiation therapy within 4 weeks prior to starting study treatment, or limited field of radiation for palliation within 2 weeks of the first dose of study treatment
- •10.Recent major surgery within 4 weeks prior to entry into the study (excluding the placement of vascular access) which would prevent administration of study treatment
- •11.History of hypersensitivity to AZD6244, docetaxel, or any excipient of these agents
- •12.Brain metastases or spinal cord compression unless asymptomatic, treated and stable off steroids and anti-convulsants for at least 3 months
- •13.Laboratory values as listed below (from laboratory results at Visit 1):
- •-ANC <1.5 x 109/L (1500 per mm3)
- •-Platelets <100 x 109/L (100,000 per mm3)
- •-Haemoglobin ?9.0 g/dL
- •-Serum bilirubin >Upper Limit of Normal (ULN)
- •-AST or ALT:
- •§>2.5 x ULN if no liver metastasis
- •§Between 3.5 x ULN and 5 x ULN, if liver metastasis present and ALP >6 x ULN
- •§>5 x ULN, if liver metastasis present
- •14.Cardiac conditions as follows:
- •-Uncontrolled hypertension (BP ?150/95 despite optimal therapy)
- •-Heart failure NYHA Class II or above
- •-Prior or current cardiomyopathy
- •-Baseline LVEF ?50%
- •-Atrial fibrillation with heart rate >100 bpm
- •-Unstable ischaemic heart disease (myocardial infarction within 6 months prior to starting treatment, or angina requiring use of nitrates more than once weekly)
- •15.Any evidence of severe or uncontrolled systemic disease, active infection, active bleeding diatheses or renal transplant, including any patient known to have hepatitis B, hepatitis C or human immunodeficiency virus (HIV)
- •16.Refractory nausea and vomiting, chronic gastrointestinal diseases (eg, inflammatory bowel disease), or significant bowel resection that would preclude adequate absorption
- •17.History of another primary malignancy within 5 years prior to starting study treatment, except for adequately treated basal or squamous cell carcinoma of the skin or cancer of the cervix in situ and the disease under study
- •18.Female patients who are breast-feeding or male or female patients of reproductive potential who are not employing an effective method of birth control
- •19.Clinical judgement by the investigator that the patient should not participate in the study
- •Exclusion criteria for participation in the optional host genetics research component of the study:
- •1.Previous allogeneic bone marrow transplant
- •2.Whole blood transfusion within 120 days of the date of host genetic sample collection (except for leukocyte depleted blood transfusion, which is allowed).
研究者
相似试验
进行中（未招募）
1 期
Estudio para determinar la seguridad y eficacia de la inyección de recMAGE-A3 en pacientes con cáncer de vejiga musculo invasivo positivos a MAGE-A3 tras cistectomia.Patients who get a cystectomy due to muscle invasive bladder cancer which is MAGE-A3 positiveMedDRA version: 14.0Level: LLTClassification code 10022877Term: Invasive bladder cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-024355-85-ESEAU Research Foundation273
进行中（未招募）
1 期
Ensayo en fase II, aleatorizado, doble ciego, controlado con placebo para evaluar la eficacia y la seguridad de ZD6474 en combinación con Arimidexâ?frente a Arimidexâ?solo como tratamiento de segunda línea en pacientes con cáncer de mama avanzado (CMA) hormonosensible (receptores de estrógeno positivos y/o receptores de progesterona positivos).Cáncer de mama avanzado (CMA) hormono sensible (ER+ve y/o PR+ve)EUCTR2005-003591-38-ESAstraZeneca AB64
进行中（未招募）
不适用
Ensayo en fase IIa, aleatorizado, doble ciego, controlado con placebo y de comparación intra-individual entre los miembros izquierdo-derecho en 25 pacientes con dermatitis atópica moderada, para investigar la eficacia, irritación local, seguridad, tolerabilidad y farmacocinética de la aplicación tópica dos veces al día con crema ImCOOH al 10% durante 14 días y una aplicación adicional en el día 15. (Phase IIa, randomized, double-blind, placebo-controlled, intra-individual left-right limb comparison trial in 25 patients with moderate atopic dermatitis to investigate the efficacy, local irritation, safety, tolerability and pharmacokinetics of twice daily topical applications with 10% ImCOOH cream for 14 days with an additional morning application on Day 15.)dermatitis atópica (atopic dermatitis)MedDRA version: 9.1Level: LLTClassification code 10012438Term: Dermatitis atopicEUCTR2007-004011-54-ESValletta Health BV
进行中（未招募）
1 期
Ensayo en fase II, aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia y la seguridad de ZD6474 en combinación con docetaxel (Taxotereâ) frente a docetaxel solo como tratamiento de segunda línea del cáncer de mama avanzado (CMA).Cáncer de mama avanzado (CMA)EUCTR2005-003592-20-ESAstraZeneca AB65
进行中（未招募）
不适用
Ensayo de fase 2, aleatorizado, en simple ciego y controlado con placebo, de la seguridad, la capacidad inmunógena y la tolerabilidad de la vacuna rLP2086 frente al meningococo de serogrupo B (MnB) a dosis de 60 microgramos, 120 microgramos y 200 microgramos en adolescentes sanos de 11 a 18 añosA Randomized, Single-Blind, Placebo-Controlled, Phase 2 Trial of the Safety, Immunogenicity, and Tolerability of Meningococcal Serogroup B (MnB) rLP2086 Vaccine at Doses of 60 micrograms, 120 micrograms, and 200 micrograms in Healthy Adolescents Aged 11 to 18 YearsVacuna rLP2086 frente al meningococo de serogrupo BThe test is a vaccine. The subjects are healthy adolescents.MedDRA version: 9.1Level: LLTClassification code 10027202Term: Meningitis bacterialEUCTR2008-007789-51-ESWyeth Research Division of Wyeth Pharmaceuticals Inc.715